Taken together, the results of the present study suggest a potential of the FXR agonist, OCA, for inhibiting HCC proliferation, migration, and invasion via interfering with the activation of IL-6/STAT3 signalling pathway. This evidence concerns the gene STAT3 and hepatocellular carcinoma.